Is Intellia Therapeutics (NTLA) Cheap Or Pricey On Its New Chief Medical Officer Appointment?

Intellia Therapeutics (NTLA) has turned investor attention toward its leadership bench after appointing Jing L. Marantz as Executive Vice President and Chief Medical Officer, a move that reshapes oversight of its development and regulatory efforts.

Against that appointment, Intellia Therapeutics trades at US$11.42, with a 7 day share price return down 12.62% and a 30 day return down 5.93%, even though the 90 day move is up 4.58% and the year to date share price return sits at 24%. That short term bounce contrasts with a much tougher run for longer term holders, where the 1 year total shareholder return is down 53.86% and the 5 year total shareholder return is down 91.32%. This signals that recent technical upgrades and FDA related speculation are being weighed against years of losses and execution risk.

Spot similar high-risk, high-reward biotech stories on our curated list of 33 healthcare AI stocks, which pairs complex science with binary regulatory milestones.

That kind of whiplash in Intellia Therapeutics raises a simple fork in the road. Are traders just cycling through FDA optimism, or does the current share price already stretch what the underlying business supports?

Most Popular Narrative: 52% Undervalued

Against the last close at $11.42, the most followed narrative pegs Intellia Therapeutics' fair value near $23.94, which implies a wide gap that only closes if the business delivers on ambitious trial and revenue expectations under a 7.48% discount rate.

Growing patient and physician enthusiasm for Intellia's lead in vivo CRISPR therapies is driving faster-than-expected enrollment across multiple late-stage clinical trials (including an expanded 1,200-patient ATTR cardiomyopathy study and strong uptake in HAE). This is positioning the company to achieve meaningful clinical readouts and regulatory milestones ahead of prior guidance. This in turn advances timelines to potential commercialization and drives long-term revenue growth prospects.

See why 88 investors see Intellia Therapeutics as 52% undervalued.

Result: Fair Value of $23.94 (UNDERVALUED)

Still, Intellia Therapeutics faces two swing factors. Any clinical or safety setback in its late stage trials, or tighter funding conditions, could quickly challenge that view of the stock being 52% undervalued.

Find out about the key risks to this Intellia Therapeutics narrative.

Another View: Intellia Therapeutics Looks Expensive On Sales

The DCF-led fair value of $23.94 presents Intellia Therapeutics as undervalued, yet the P/S ratio tells a very different story. At 26.9x sales against a fair ratio of 0.1x, the stock appears extremely expensive on revenue and remains higher than the US Biotechs average of 11.2x. For investors weighing these conflicting signals, it may be useful to consider which metric is more closely aligned with how this business generates revenue from CRISPR over time.

See what the numbers indicate about this price in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of enthusiasm and concern around Intellia Therapeutics feels conflicted, treat that as your cue to move quickly and review the data yourself, weighing the balance of risks and potential upsides set out in the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Intellia Therapeutics?

If Intellia Therapeutics has sharpened your focus on risk and reward, keep that momentum. Use data driven filters to surface fresh opportunities that match your style.

• Target potential underpriced opportunities before the crowd by scanning our curated pool of 33 high quality undervalued stocks.
• Strengthen your downside protection by focusing on companies with robust finances using the list of solid balance sheet and fundamentals (25 results).
• Add income focused candidates to your watchlist by reviewing the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com